Symposium on antimicrobial therapy. VII. The fluoroquinolones
Abstract
The fluoroquinolones represent an important addition to the antimicrobial armamentarium. They are, however, commonly overused. It is estimated that in 1989, ciprofloxacin was prescribed for 1 in every 44 Americans. This observation demonstrates not only the overusage, but the economic incentive for development of additional fluoroquinolones. In some situations, oral fluoroquinolone therapy can reduce costs by eliminating the need for parenteral therapy and reducing the need for or the duration of hospitalization. In most situations where oral antimicrobial agents are being considered, however, the fluoroquinolones are among the most expensive alternatives. In addition to concerns about cost factors, it is important to reiterate concern that widespread overuse of these agents will promote the development of microbial resistance and ultimately limit their usefulness. The clinical usefulness of the fluoroquinolones is summarized in Table 4. As can be seen, the fluoroquinolones are the "possibly preferred agent" in very few infections: complicated urinary tract infections due to Gram-negative bacilli resistant to other oral antimicrobial agents, severe bacterial gastroenteritis, exacerbations of lower respiratory tract infection in patients with cystic fibrosis, osteomyelitis due to Gram-negative bacilli sensitive to the fluoroquinolones, and invasive external otitis. They are alternative agents in a number of other infections when sensitive Gram-negative bacilli are the…
Read the paper
Related studies
- Horizontal gene transfer in the human gastrointestinal tract: potential spread of antibiotic resistance genes
- Mutation supply and relative fitness shape the genotypes of ciprofloxacin-resistant Escherichia coli
- Genomic Survey of E. coli From the Bladders of Women With and Without Lower Urinary Tract Symptoms
- Characterization of cefotaxime-resistant urinary Escherichia coli from primary care in South-West England 2017–18
- Fitness cost constrains the spectrum of marR mutations in ciprofloxacin-resistant Escherichia coli
- Emerging evidence-based innovative approaches to control catheter-associated urinary tract infection: a review
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.